Treatment of lateral epicondylitis with botulinum toxin. A randomized, double-blind, placebo-controlled trial

被引:106
|
作者
Wong, SM [1 ]
Hui, ACF [1 ]
Tong, PY [1 ]
Poon, DWF [1 ]
Yu, E [1 ]
Wong, LKS [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.7326/0003-4819-143-11-200512060-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Lateral epicondylitis is a common condition for which botulinum toxin has been reported to have a therapeutic role in uncontrolled studies. Objective: To determine if an injection of botulinum toxin is more effective than placebo for reducing pain in adults with lateral epicondylitis. Design: Randomized, double-blind, placebo-controlled trial conducted from September 2002 to December 2004. Setting: Outpatient clinics at a university hospital and a district hospital in Hong Kong. Participants: 60 patients with lateral epicondylitis. Measurements: The primary outcome was change in subjective pain as measured by a 100-mm visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst pain ever) at 4 weeks and 12 weeks. All patients completed post-treatment follow-up. Interventions: A single injection of 60 units of botulinum toxin type A or normal saline placebo. Results: Mean VAS scores for the botulinum group at baseline and at 4 weeks were 65.5 mm and 25.3 mm, respectively; respective scores for the placebo group were 66.2 mm and 50.5 mm (between-group difference of changes, 24.4 mm [95% CI, 13.0 to 35.8 mm]; P < 0.001). At week 12, mean VAS scores were 23.5 mm for the botulinum group and 43.5 mm 1:or the placebo group (between-group difference of changes, 19.3 mm [CI, 5.6 to 32.9 mm]; P = 0.006). Grip strength was not statistically significantly different between groups at any time. Mild paresis of the fingers occurred in 4 patients in the botulinum group at 4 weeks. One patient's symptoms persisted until week 12, whereas none of the patients receiving placebo had the same complaint. At 4 weeks, 10 patients in the botulinum group and 6 patents in the placebo group experienced weak finger extension on the same side as the injection site. Limitations: The trial was small, and most participants were women. The blinding protocol may have been ineffective because the 4 participants who experienced paresis of the fingers could have correctly assumed that they received an active treatment. Conclusions: Botulinum toxin injection may improve pain over a 3-month period in some patients with lateral epicondylitis, but injections may be associated with digit paresis and weakness of finger extension.
引用
收藏
页码:793 / 797
页数:5
相关论文
共 50 条
  • [1] Treatment of chronic radial epicondylitis with botulinum toxin A - A double-blind, placebo-controlled, randomized multicenter study
    Placzek, Richard
    Drescher, Wolf
    Deuretzbacher, Georg
    Hempfing, Axel
    Meiss, A. Ludwig
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2007, 89A (02): : 255 - 260
  • [2] BOTULINUM TOXIN FOR ACHALASIA - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    PASRICHA, PJ
    RAVICH, WJ
    HENDRIX, TR
    JONES, B
    SOSTRE, SJ
    KALLOO, AN
    GASTROENTEROLOGY, 1994, 106 (04) : A156 - A156
  • [3] A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis
    Schnider, P
    Binder, M
    Kittler, H
    Birner, P
    Starkel, D
    Wolff, K
    Auff, E
    BRITISH JOURNAL OF DERMATOLOGY, 1999, 140 (04) : 677 - 680
  • [4] Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial
    Simpson, DM
    Alexander, DN
    OBrien, CF
    Tagliati, M
    Aswad, AS
    Leon, JM
    Gibson, J
    Mordaunt, JM
    Monaghan, EP
    NEUROLOGY, 1996, 46 (05) : 1306 - 1310
  • [5] Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study
    Evers, S
    Vollmer-Haase, J
    Schwaag, S
    Rahmann, A
    Husstedt, IW
    Frese, A
    CEPHALALGIA, 2004, 24 (10) : 838 - 843
  • [6] DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BOTULINUM TOXIN INJECTIONS FOR THE TREATMENT OF SPASMODIC TORTICOLLIS
    GREENE, P
    KANG, U
    FAHN, S
    BRIN, M
    MOSKOWITZ, C
    FLASTER, E
    NEUROLOGY, 1990, 40 (08) : 1213 - 1218
  • [7] Neck pain in chronic whiplash syndrome treated with botulinum toxin. A double-blind, placebo-controlled clinical trial
    M. Padberg
    S.F.T.M. de Bruijn
    D.L.J. Tavy
    Journal of Neurology, 2007, 254 : 290 - 295
  • [8] Neck pain in chronic whiplash syndrome treated with botulinum toxin. A double-blind, placebo-controlled clinical trial
    Padberg, M.
    de Bruijn, S. F. T. M.
    Tavy, D. L. J.
    JOURNAL OF NEUROLOGY, 2007, 254 (03) : 290 - 295
  • [9] Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial
    Silberstein, SD
    Stark, SR
    Lucas, SM
    Christie, SN
    DeGryse, RE
    Turkel, CC
    MAYO CLINIC PROCEEDINGS, 2005, 80 (09) : 1126 - 1137
  • [10] Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial
    Wu, Chuan-Jie
    Lian, Ya-Jun
    Zheng, Ya-Ke
    Zhang, Hai-Feng
    Chen, Yuan
    Xie, Nan-Chang
    Wang, Li-Jun
    CEPHALALGIA, 2012, 32 (06) : 443 - 450